Global Cancer Biopsy Market 2022-2028

A biopsy is the removal of tissue from any part of the body to examine it for disease. Some may remove a small tissue sample with a needle while others may surgically remove a suspicious nodule or lump. Biopsies are frequently used to diagnose cancer, but they can help identify other conditions such as infections and inflammatory and autoimmune disorders. They may also be done to match organ tissue before a transplant and to look for signs of organ rejection following a transplant. Gen Consulting Company estimates the global cancer biopsy market will total USD 43,692 million by 2028, an average annual growth of 10.7 percent during the forecast period, according to the latest edition of the Global Cancer Biopsy Market Report.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cancer biopsy market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cancer biopsy industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the component, disease indication, biopsy type, and region. The global market for cancer biopsy can be segmented by component: instruments, kits & consumables, services. Cancer biopsy market is further segmented by disease indication: blood cancer, breast cancer, cervical cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, others. Based on biopsy type, the cancer biopsy market is segmented into: tissue biopsies, liquid biopsies, others. On the basis of region, the cancer biopsy market also can be divided into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By component:
- instruments
- kits & consumables
- services

By disease indication:
- blood cancer
- breast cancer
- cervical cancer
- colorectal cancer
- kidney cancer
- liver cancer
- lung cancer
- ovarian cancer
- pancreatic cancer
- prostate cancer
- skin cancer
- others

By biopsy type:
- tissue biopsies
- liquid biopsies
- others

By region:
- North America
- Asia Pacific
- Europe
- Rest of the World (ROW)

The report also provides analysis of the key companies of the industry and their detailed company profiles including ANGLE plc, Becton, Dickinson and Company, Biocept, Inc., Biodesix, Inc. (Integrated Diagnostics), Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Freenome Holdings, Inc., GRAIL, LLC, Guardant Health, Inc., Helio Health Inc., Hologic, Inc., Illumina, Inc., Lucence Health Inc., Myriad Genetics, Inc., Oncimmune Holdings PLC, Qiagen N.V., Thermo Fisher Scientific, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
- To analyze and forecast the market size of the global cancer biopsy market.
- To classify and forecast the global cancer biopsy market based on component, disease indication, biopsy type, region.
- To identify drivers and challenges for the global cancer biopsy market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cancer biopsy market.
- To identify and analyze the profile of leading players operating in the global cancer biopsy market.

Why Choose This Report
- Gain a reliable outlook of the global cancer biopsy market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.